Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, yesterday provided updated...

Education Management Solutions (EMS), a leading provider of healthcare simulation and competency management platforms, proudly announces its continued role as the Presidential Sponsor of the...

TETRA Technologies, Inc. ("TETRA" or the "Company") (NYSE: TTI) announced that its senior management will be participating in the following investor conferences. Jefferies 11th Annual Virtual...

New Feature Simplifies How Organizations Manage Applications Across Entire Edge Environments LAS VEGAS, Dec. 9, 2025 /PRNewswire/ -- Gartner IT Infrastructure, Operations & Cloud Strategies Conference

Recently recognized with a CES 2026 Innovation Award, the solution combines video decoding, AI inference, and encoding on a single chip, offering 80% hardware cost savings compared to GPU...

Hyundai Mobis to participate in CES 2026 next month… hosting an invitation-only private booth to focus on new business opportunities To be showcased: M.VICS 7.0 cockpit integrated solution,...

LBA-2: Primary results from VAYHIT2, a randomized, double-blind, phase 3 trial of ianalumab plus eltrombopag versus placebo plus eltrombopag in patients with primary immune thrombocytopenia (ITP)...

LBA-5: A hospital policy of tranexamic acid to reduce transfusion in major non-cardiac surgery: The TRACTION trial ORLANDO, Fla., Dec. 9, 2025 /PRNewswire/ -- When hospitals were randomly assigned...

LBA-3: Pirtobrutinib vs Bendamustine Plus Rituximab (BR) in Patients with CLL/SLL: First Results from a Randomized Phase III Study Examining a Non-Covalent BTK Inhibitor in Untreated Patients...

LBA-6: Phase 3 randomized study of teclistamab plus daratumumab versus investigator's choice of daratumumab and dexamethasone with either pomalidomide or bortezomib (DPd/DVd) in patients (Pts)...